Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 15/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 2/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3128252 | 0.85 | SCN9A (0.53) | SCN9APTPN1BRAF | |
| SCHEMBL3131766 | 0.81 | HDAC1 (0.44) | HDAC1HDAC8HDAC6KDM4EALDH1A1 | |
| SCHEMBL3133764 | 0.78 | THRA (0.54) | SCN9APTPN1BRAF | |
| SCHEMBL3130767 | 0.76 | MEN1 (0.37) | HDAC1HDAC8HDAC6ALDH1A1 | |
| SCHEMBL3136233 | 0.76 | HDAC1 (0.42) | HDAC1HDAC8HDAC6ALDH1A1 | |
| SCHEMBL3133756 | 0.74 | HDAC1 (0.40) | SCN9AHDAC1HDAC8HDAC6PTPN1 | |
| SCHEMBL3141283 | 0.74 | HTT (0.44) | HDAC1HDAC8HDAC6KDM4EALDH1A1 | |
| SCHEMBL6954319 | 0.71 | PTPN1 (0.53) | SCN9AHDAC1HDAC8PTPN1BRAF | |
| SCHEMBL25284297 | 0.68 | L3MBTL1 (0.44) | ALDH1A1 | |
| SCHEMBL23042415 | 0.67 | HTT (0.43) | HDAC1HDAC8HDAC6KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004271-A1 | HETEROCYCLIC COMPOUNDS AS AGANIST FOR THE THYROID RECEPTOR | KARO BIO AB (SE) | 2010-01-07 | — | — | US | disclosed |
| EP-1899309-A1 | HETEROCYCLIC COMPOUNDS AS AGONISTS FOR THE THYROID RECEPTOR | KARO BIO AB (SE) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007003419-A1 | HETEROCYCLIC COMPOUNDS AS AGONISTS FOR THE THYROID RECEPTOR | KARO BIO AB (SE) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004271-A1 | HETEROCYCLIC COMPOUNDS AS AGANIST FOR THE THYROID RECEPTOR | TSHR, GHSR, TRHR | SCN9A 3770/4885HDAC1 264/4885HDAC8 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.